Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

Toxicity Study of Streptococcus pneumoniae Vaccine Administrated Subcutaneously in Rats

  • Received : 2011.02.10
  • Accepted : 2011.05.15
  • Published : 2011.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

This study was performed to evaluate the toxicity of polysaccharide-based Streptococcus pneumoniae vaccine in Specific Pathogen Free (SPF), Sprague-Dawley (SD) rats. S. pneumoniae vaccine was administrated subcutaneously each dose level of high (560 ${\mu}g$/rat), medium (280 ${\mu}g$/rat) and low (140 ${\mu}g$/rat) on days 0, 14, 28. The rats were observed for 2 weeks or 4 weeks after the final injection. During this test, there were no significant dose-dependent changes in body weight, water and food consumption. In urinalysis and serum chemistry, dose-related changes were not detected. In hematology, the percent of neutrophils and lymphocytes in white blood cells were changed significantly. According to the measurement of organ weight, only spleen weight was significantly increased in all groups of administration compared to the control group. In the histopathological examination, an antigen-deposit, vacuolated macrophages, infiltrated inflammatory cells and a formation of granulation tissue were observed at the site of an administration. These results are considered as an outcome by immune responses through a vaccination. Consequently, the results of this study demonstrated that S. pneumoniae vaccine has no toxicity when it was administrated subcutaneously three times in 2-week interval at a high dose of 560 ${\mu}g$/rat.

Keywords

References

  1. Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R. and Edwards, K. (2000). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J., 19, 187-195. https://doi.org/10.1097/00006454-200003000-00003
  2. Charles, A.J., Paul, T., Mark, W. and Mark, S. (2005). ImmunoBiology-the immune system in health and disease (6th edition), Garland Science, NewYork, pp. 12-23.
  3. Daoust, V., Carlo, D.J., Zelther, J.Y. and Perry, M.B. (1981). Specific Capsular polysaccharide of Type 45 Streptococcus pneumonia (American Type 72). Infect. Immun., 32, 1028-1033.
  4. Fenske, D.B., Chonn, A. and Cullis, P.R. (2008). Liposomal Nanomedicines: An Emerging Field. Toxicol. Pathol., 36, 21-29. https://doi.org/10.1177/0192623307310960
  5. Hausdorff, W.P., Feikin, D.R. and Klugman, K.P. (2005). Epidemiological differences among pneumococcal serotypes. Lancet. Infect. Dis., 5, 83-93. https://doi.org/10.1016/S1473-3099(05)01280-6
  6. Henriksen-Lacey, M., Bramwell, V.W., Christensen, D., Agger, E.M., Andersen, P. and Perrie, Y. (2010). Liposome based on dimethyldioctadecylammonium promote a depot effect and enhance immungenicity of soluble antigen. J. Control. Release., 142, 180-186. https://doi.org/10.1016/j.jconrel.2009.10.022
  7. Korea Food & Drug administration (2008): Guideline on Nonclinical Evaluation of Biopharmaceuticals, 11-147000 0-001713-14.
  8. Korea Food & Drug administration (2008). Food & Drug statistical yearbook, 11-1470000-000023-10.
  9. Meng, C., Lin, H., Huang, J., Wang, H., Cai, Q., Fang, L. and Guo, Y. (2009). Development of 5-valent conjugate pneumococcal protein A-capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Microb. Pathog., 47, 151-156. https://doi.org/10.1016/j.micpath.2009.05.004
  10. Pletz, M.W., Maus, U., Krug, N., Welte, T. and Lode, H. (2008). Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int. J. Antimicrob. Agents., 32, 199-206. https://doi.org/10.1016/j.ijantimicag.2008.01.021
  11. Rao, M. and Alving, C.R. (2000). Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. Adv. Drug. Deliy. Rev., 41, 171-188. https://doi.org/10.1016/S0169-409X(99)00064-2
  12. Richard, A.G., Thomas, J.K., Barbara, A.O. and Janis, K. (2003). Immunology (5th edition), W.H.Freeman, NewYork, pp. 335-336.
  13. Ring, A., Weiser, J.N. and Tuomanen, E.I. (1998). Pneumococcal Trafficking across the Blood-Brain Barrier. Molecular Analysis of a Novel Bidirectional Pathway. J. Clin. Invest., 102, 347-360. https://doi.org/10.1172/JCI2406

Cited by

  1. Dose site reactions and related findings after vaccine administration in safety studies vol.36, pp.8, 2016, https://doi.org/10.1002/jat.3314